Fintel reports that on January 31, 2025, Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (NasdaqGM:ACRV) with a Overweight recommendation. Analyst Price Forecast Suggests 260.44% Upside ...

Alongside record profits, USDT issuer Tether also reported Friday it now holds over $143 billion in reserve assets to back ...

Tether Holdings Ltd., the stablecoin issuer that was pulled into the spotlight this week during the confirmation hearing for ...

All else equal, this would increase gasoline prices, which in most of the country have averaged $3 per gallon for the past ...

Cantor Fitzgerald reiterated its Overweight rating and a $480.00 price target for Vertex Pharmaceuticals Incorporated (NASDAQ ...